Monocarboxylate transporters 1 and 4 and MTCO1 in gastric cancer
|Author:||Eskuri, Maarit1; Kemi, Niko1; Kauppila, Joonas H.2,3|
1Cancer and Translational Medicine Research Unit, Medical Research Center, University of Oulu and Oulu University Hospital, 90014 Oulu, Finland
2Surgery Research Unit, Medical Research Center, University of Oulu and Oulu University Hospital, 90014 Oulu, Finland
3Upper Gastrointestinal Surgery, Department of Molecular Medicine and Surgery, Karolinska Institutet and Karolinska University Hospital, 17177 Stockholm, Sweden
|Online Access:||PDF Full Text (PDF, 18.1 MB)|
|Persistent link:|| http://urn.fi/urn:nbn:fi-fe2021061036465
Multidisciplinary Digital Publishing Institute,
|Publish Date:|| 2021-06-10
Background: Monocarboxylate transporters (MCTs) appear to play an important role in tumor development and aggressiveness. The present study aimed to evaluate associations between cytoplasmic MCT1, MCT4, and mitochondrial cytochrome c oxidase (MTCO1) expression and clinicopathological variables or survival in gastric cancer.
Material and methods: A total of 568 gastric adenocarcinoma patients were included in this retrospective cohort study. Protein expressions were detected by immunohistochemical staining. The patients were divided into low expression and high expression groups by median value. The Chi-squared test was used to compare categorical variables. The T-test was used to compare continuous variables. Expressions were analyzed in relation to 5-year survival and overall survival. Cox regression provided HRs and 95% CIs, adjusted for confounders.
Results: High cytoplasmic MCT1 expression was associated statistically significantly with higher T-class (p = 0.020). High cytoplasmic MCT4 expression was associated statistically significantly with positive lymph node status (p = 0.005) and was more common in Lauren’s intestinal type (p < 0.001). Low cytoplasmic MTCO1 expression was associated statistically significantly with positive distant metastases (p = 0.030), and high cytoplasmic MTCO1 expression was associated more often with intestinal type (p = 0.044). However, MCT1, MCT4, and MTCO1 were not associated with survival.
Conclusions: Monocarboxylate receptors seem to be associated with gastric cancer progression but have no independent prognostic relevance.
|Type of Publication:||
A1 Journal article – refereed
|Field of Science:||
This study was supported by grants from The Finnish Medical Foundation (M.E), Orion Research Foundation (J.H.K.), Thelma Mäkikyrö Foundation (J.H.K.) and Mary and Georg C. Ehrnroot Foundation (J.H.K.), Päivikki and Sakari Sohlberg Foundation (J.H.K.), The Finnish Cancer Foundation (J.H.K.), and Sigrid Juselius Foundation (J.H.K.). The study sponsors had no role in the design of the study, data collection, analysis or interpretation of the results, writing of the manuscript, or the decision to submit the manuscript for publication.
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).